Nesiritide (BNP) dosing & administration
Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much Nesiritide (BNP) do I take?
Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
2 documented dose levels — separate regimens, not a titration schedule
2 mcg/kg IV bolus
Frequency
Single bolus at initiation
Duration
One-time loading dose
Timing
Best time to take
Nesiritide (BNP) is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of Nesiritide (BNP) is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
If stacking
Nesiritide (BNP) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use Nesiritide (BNP)?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Nesiritide (BNP) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Nesiritide (BNP) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intravenous (IV) bolus—rotate sites if applicable
Maintain a consistent schedule for optimal results with Nesiritide (BNP). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is Nesiritide (BNP) safe?
Side effects
Commonly reported: Headache, Lightheadedness, Back pain
Less common: Hypotension (low blood pressure), Abdominal pain, Insomnia
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Nesiritide (BNP)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Nesiritide (BNP) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Excessive diuretics — Combined effect can cause dangerous dehydration and kidney injury; must be carefully monitored
- Other potent vasodilators in high doses — Risk of dangerously low blood pressure; requires careful dosage adjustment and monitoring
- Nephrotoxic drugs (NSAIDs, contrast dye) — Nesiritide-related kidney effects may be worsened; avoid if possible during treatment
Published research
What the studies show
Burger AJ, et al. · 2002
Nesiritide was developed as a recombinant B-type natriuretic peptide for intravenous treatment of acute decompensated heart failure. FDA approved the drug in August 2001, marking a breakthrough in acute heart failure management.
O'Connor CM, Starling RC, Hernandez AF, et al. · 2011
N Engl J Med 2011;365:32-43 (PMID 21732835). ASCEND-HF randomized 7,141 hospitalized acute heart failure patients to nesiritide or placebo. Dyspnea improved slightly (6 h: 44.5% vs 42.1%; 24 h: 68.2% vs 66.1%) but missed prespecified significance. There was no difference in 30-day death or heart-failure rehospitalization (9.4% vs 10.1%) or in worsening renal function (31.4% vs 29.5%), and hypotension was more frequent. The authors concluded nesiritide cannot be recommended for routine use in the broad acute heart failure population.
Topol EJ · 2005
Critical review raised questions about nesiritide's long-term clinical benefits despite its short-term hemodynamic improvements. Safety concerns and limited evidence for mortality reduction prompted ongoing evaluation of its clinical role.
Burnett JC Jr, Korinek J · 2008
Despite controversy over long-term outcomes, nesiritide remains useful for rapid symptom relief in acute heart failure. Ongoing research clarifies its optimal use, patient selection, and role in modern heart failure management.
U.S. Food and Drug Administration / Scios (reproduced by RxList) · 2019
Natrecor is no longer listed on DailyMed or openFDA and the accessdata label PDF no longer resolves, so this cites RxList's reproduction of the label (revised Jan 2019). Indicated for acutely decompensated heart failure with dyspnea at rest or minimal activity; reduced PCWP and improved 3-hour dyspnea. Dosing: 2 mcg/kg IV bolus then 0.01 mcg/kg/min. In VMAC, 60% of the 3-hour PCWP reduction occurred within 15 minutes of the bolus. Hypotension is dose-limiting (12% vs 4% placebo); headache 7% vs 6%. PK half-life is 18 minutes. Worsening renal function: creatinine >0.5 mg/dL above baseline in 28% (Natrecor) vs 21% (nitroglycerin) through day 30 in VMAC.
Burnett JC Jr, Korinek J · 2008
Circulation: Heart Failure perspective on nesiritide (recombinant human B-type natriuretic peptide) — its approval for acute decompensated heart failure, the later controversy over its safety, and its prospects.
Head to head
Nesiritide (BNP) compared
Studied for
Conditions Nesiritide (BNP) has been researched in
Want the full picture?
The complete Nesiritide (BNP) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.